Pharmacological treatment of anxiety disorders: current treatments and future directions.
Pharmacological treatment of anxiety disorders: current treatments and future directions.
复制标题
DOI：
10.1016/j.janxdis.2012.07.009
复制
发表时间：
2012-12
影响因子：
10.3
通讯作者：
Roy-Byrne, Peter P.
中科院分区：
文献类型：
--
作者：
Farach, Frank J.;Pruitt, Larry D.;Jun, Janie J.;Jerud, Alissa B.;Zoellner, Lori A.;Roy-Byrne, Peter P.
与 30 年前相比，现代药物治疗焦虑症更安全、更耐受。不幸的是，尽管人们对焦虑的病理生理学有了更多的了解，但在大多数情况下，治疗效果和持续时间并未得到改善。此外，尽管在药物开发上投入了数十亿美元的研究资金，但创新疗法尚未进入市场。在回顾有关当前治疗方法的文献时，我们认为基于证据的实践将受益于对治疗反应不完全的原因以及药物组合和测序的比较疗效的更好的研究。我们还调查了开发创新焦虑疗法的两种主要方法：基于特定神经受体的药物的持续开发和恐惧相关记忆的药理学操纵。我们强调了未来研究的方向，因为这两种方法都尚未准备好用于常规临床使用。
Modern pharmacological treatments for anxiety disorders are safer and more tolerable than they were 30 years ago. Unfortunately, treatment efficacy and duration have not improved in most cases despite a greater understanding of the pathophysiology of anxiety. Moreover, innovative treatments have not reached the market despite billions of research dollars invested in drug development. In reviewing the literature on current treatments, we argue that evidence-based practice would benefit from better research on the causes of incomplete treatment response as well as the comparative efficacy of drug combinations and sequencing. We also survey two broad approaches to the development of innovative anxiety treatments: the continued development of drugs based on specific neuroreceptors and the pharmacological manipulation of fear-related memory. We highlight directions for future research, as neither of these approaches is ready for routine clinical use.
登录
查看更多内容
影响因子：
2.4
作者：
Cahill, L;McGaugh, JL
通讯作者：
McGaugh, JL
影响因子：
4.4
作者：
Aikens, JE;Nease, DE;Schwenk, TL
通讯作者：
Schwenk, TL
影响因子：
1.7
作者：
BAKISH, D;HOOPER, CL;BASHIR, F
通讯作者：
BASHIR, F
影响因子：
10.6
作者：
Davidson, JRT;Weisler, RH;van Meter, S
通讯作者：
van Meter, S
影响因子：
6.9
作者：
Christiana, JM;Gilman, SE;Kessler, RC
通讯作者：
Kessler, RC